ImmunityBio (IBRX) Free Cash Flow Growth (3y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 24.91% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 20.11% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.71% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.65% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 31.42% |
| 10 | ImmunityBio | 7.72 Bn | 7.34 Bn | 43.97 Mn | 9.27% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.27% |
| Dec 31, 2025 | 7.80% |
| Sep 30, 2025 | 3.97% |
| Jun 30, 2025 | 7.85% |
| Mar 31, 2025 | -4.17% |
| Dec 31, 2024 | -10.15% |
| Sep 30, 2024 | -5.08% |
| Jun 30, 2024 | -11.11% |
| Mar 31, 2024 | -18.69% |
| Dec 31, 2023 | -29.38% |
| Sep 30, 2023 | -38.39% |
| Jun 30, 2023 | -14.84% |
| Mar 31, 2023 | -48.63% |
| Dec 31, 2022 | 5.10% |
| Sep 30, 2022 | -61.89% |
| Jun 30, 2022 | -86.01% |
| Mar 31, 2022 | -71.33% |
| Dec 31, 2021 | -98.92% |
| Sep 30, 2021 | -60.34% |
| Jun 30, 2021 | -57.78% |
| Mar 31, 2021 | -46.92% |
| Dec 31, 2020 | -518.97% |
| Sep 30, 2020 | -21.06% |
| Jun 30, 2020 | -27.62% |
| Mar 31, 2020 | -29.28% |
| Dec 31, 2019 | -106.35% |
| Sep 30, 2019 | -10.89% |
| Jun 30, 2019 | -19.84% |
| Mar 31, 2019 | -15.04% |
| Dec 31, 2018 | 13.73% |
| Sep 30, 2018 | -58.50% |
| Jun 30, 2018 | -86.24% |
| Mar 31, 2018 | -40.18% |
| Dec 31, 2017 | 27.91% |
| Sep 30, 2017 | -181.57% |
| Jun 30, 2017 | -124.10% |
| Mar 31, 2017 | -626.42% |